RENB vs. OVID, PRLD, FHTX, ME, MACK, GALT, DSGN, CDT, GTHX, and ACIU
Should you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Ovid Therapeutics (OVID), Prelude Therapeutics (PRLD), Foghorn Therapeutics (FHTX), 23andMe (ME), Merrimack Pharmaceuticals (MACK), Galectin Therapeutics (GALT), Design Therapeutics (DSGN), Conduit Pharmaceuticals (CDT), G1 Therapeutics (GTHX), and AC Immune (ACIU). These companies are all part of the "pharmaceutical preparations" industry.
Renovaro (NASDAQ:RENB) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
Ovid Therapeutics has a consensus price target of $8.08, suggesting a potential upside of 163.30%. Given Ovid Therapeutics' higher probable upside, analysts clearly believe Ovid Therapeutics is more favorable than Renovaro.
Renovaro has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -13,351.53%. Ovid Therapeutics' return on equity of -49.76% beat Renovaro's return on equity.
Renovaro has higher earnings, but lower revenue than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks.
Renovaro has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.
In the previous week, Ovid Therapeutics had 8 more articles in the media than Renovaro. MarketBeat recorded 9 mentions for Ovid Therapeutics and 1 mentions for Renovaro. Ovid Therapeutics' average media sentiment score of 0.79 beat Renovaro's score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the news media.
71.4% of Renovaro shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 21.7% of Renovaro shares are owned by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Ovid Therapeutics received 344 more outperform votes than Renovaro when rated by MarketBeat users.
Summary
Ovid Therapeutics beats Renovaro on 10 of the 15 factors compared between the two stocks.
Get Renovaro News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renovaro Competitors List
Related Companies and Tools
